Literature DB >> 7272167

Should clearance be normalised to body surface or to lean body mass?

T H Hallynck, H H Soep, J A Thomis, J Boelaert, R Daneels, L Dettli.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 7272167      PMCID： PMC1401592          DOI： 10.1111/j.1365-2125.1981.tb01163.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  ANTHROPOMETRIC EVALUATION OF BODY COMPOSITION THROUGHOUT LIFE.

Authors:  A R BEHNKE
Journal:  Ann N Y Acad Sci       Date:  1963-09-26       Impact factor: 5.691

2.  Clinical pharmacology of gentamicin in infants 2 to 24 months of age.

Authors:  G H McCracken
Journal:  Am J Dis Child       Date:  1972-12

3.  Gentamicin in the neonatal period.

Authors:  G H McCracken; L G Jones
Journal:  Am J Dis Child       Date:  1970-12

4.  [Pharmacokinetics of gentamicin in adults and children of various ages].

Authors:  C Simon; E Schmitt; V Malerczyk; C Arkenau
Journal:  Med Welt       Date:  1973-04-20

5.  Gentamicin in newborn infants. Comparison of intramuscular and intravenous administration.

Authors:  J W Paisley; A L Smith; D H Smith
Journal:  Am J Dis Child       Date:  1973-10

6.  Gentamicin: pharmacologic observations in newborns and infants.

Authors:  A W Nunnery; H D Riley
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

7.  Pharmacologic evaluation of gentamicin in newborn infants.

Authors:  G H McCracken; D F Chrane; M L Thomas
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  STUDIES OF UREA EXCRETION. III: The Influence of Body Size on Urea Output.

Authors:  J F McIntosh; E Möller; D D Van Slyke
Journal:  J Clin Invest       Date:  1928-12       Impact factor: 14.808

9.  Pharmacokinetics of gentamicin in children and adults.

Authors:  G R Siber; P Echeverria; A L Smith; J W Paisley; D H Smith
Journal:  J Infect Dis       Date:  1975-12       Impact factor: 5.226
  9 in total
  57 in total

1.  The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

Authors:  Jean-Mathieu Beauregard; Michael S Hofman; Grace Kong; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

3.  Relationships among liver and kidney volumes, lean body mass and drug clearance.

Authors:  S Nawaratne; J E Brien; E Seeman; R Fabiny; J Zalcberg; W Cosolo; P Angus; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

4.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.

Authors:  A A Vinks; J W Mouton; D J Touw; H G Heijerman; M Danhof; W Bakker
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children.

Authors:  Byung-Moon Choi; Hyun-Gu Lee; Hyo-Jin Byon; Soo-Han Lee; Eun-Kyung Lee; Hee-Soo Kim; Gyu-Jeong Noh
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-02-28       Impact factor: 2.745

7.  Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.

Authors:  U Eriksson; B Seifert; A Schaffner
Journal:  BMJ       Date:  2001-03-10

8.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Population pharmacokinetics and prophylactic anti-emetic efficacy of ramosetron in surgical patients.

Authors:  Yong-Hun Lee; Jae-Hyeon Seo; Kyung-Tae Min; Young-Jin Lim; Seong-Wook Jeong; Eun-Kyung Lee; Byung-Moon Choi; Gyu-Jeong Noh
Journal:  Br J Clin Pharmacol       Date:  2016-06-08       Impact factor: 4.335

10.  Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.

Authors:  Sven Björkman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.